Strategies to target the POSTN/AKT axis downstream of TW could utilize the following approaches alone or in combination: Delivery of POSTN blocking antibodies demonstrated to have activity in preclinical cancer models (Zhu et al., 2011), blockade of POSTN binding integrin receptors with cilengitide (Mikheev et al., 2015), and available AKT inhibitors. The gene discussed is AKT1; the disease is cancer.